becton dickinson compani
thirteenth street almost gh updat
larg expect
renaiss baltimor harborplac hotel date novemb time
ceo hole lobbi hotel chomp left
halloween candi five compani report hold call exact time
associ molecular patholog meet full swing three compani report
next day catch train new york morn analyst
day ceo full day meet distant stare glassi eye high adrenalin
constant thought mean run head
describ offici weinstein trough moral earn season
togeth
bring test low last coupl night nine
compani report span along constant barrag news
get way trough level howev could sens light
end tunnel trough hit around thursday morn
submit third edit thirteenth street note week time
ceo curl floor rock back forth listen jame taylor
sing close eye dont judg man legend talk five
empti diet dr pepper can name chicago bull start line-up
one earn call tomorrow morn meridian bioscienc peopl listen
one could prove interest bunch client call take deep breath
reassess take us long write darn earn note serious
weekend ceo get reintroduc wife kid
somehow see less even though he travel work
home get peloton shame perform past coupl week work
cloth aka sweatpant tight result mayb shave get home
haircut pictur let say advanc pretti may want
avert eye alreadi shave mustach disappoint unclear
singl person live alon actual weekend pandem mayb
better dont know
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
anyway fourth edit thirteenth street name reflect compani list report
day period essenti abridg version quasi-weekli backstreet public far prior version
public includ takeaway bullish earn call highlight
potenti undiscov covid play second segment provid thought formal first-quart releas
preview provid link brief thought relat news may
miss last week last night edit focus earn updat staar
surgic report time wednesday even may five compani report
exact time
edit thirteenth street focus company-specif updat thursday specif updat includ
thought earn updat includ brief take-away
acceler diagnost compani difficult posit given custom sole focu test
longer term pheno system still thought solut major killer sepsi think
side pandem institut place greater valu diagnost algorithm acceler
help better tune meantim focu hone messag get readi aggress effort
countri reopen advanc pipelin work get eua immunoassay platform
igg igm antibodi test acquir right
lot synthes regard crosswind busi chang
think busi longer term april revenu low doubl digit trough
look potenti area upsid includ antigen test realli big deal success
get updat shortli addit compani domin posit area benefit
addit test vaccin administr commentari alari pump ad time get
process neg comment investor seem latch onto though believ like
expect april revenu close glaucoma busi
fortun demand product still backlog patient continu grow cataract
procedur must treat face blind come focus competit play
surgeon abl manag capac limit massiv demand servic
guardant anoth big win quarter guardant despit headwind
emerg mid-march busi still put strong result got asp lift cover non-lung case
addit situat could help drive even clinician favor non-invas blood collect
hospital-bas biopsi procedur requir collect tissu biopsi addit test nobl ventur
help fill local test gap want investor think stock
need order drive valuat view
jump also want make sure investor awar approach model week intend take
time publish updat model effort thought deliber estim take
time assess hear compani report cycl take commentari consider
evalu space would rather take approach revis estim look updat next week
meantim happi discuss model thought anyon would like dig deeper
addit detail anyth discuss report schedul call us pleas contact william blair
link previou thirteenth street public
need bigger boat game chang news come test takeaway
tuesday meet cinco de mayo recap news result thought
recap recent news diagnosticsgenmark luminex shine could meridian bioscienc
ceooh yeah bad
surpris tucson updat pre-releas pheno implement hit paus due
acceler first-quart result line pre-releas mid-april join parti prereleas
remov guidanc throw curv move antibodi test much commentari relat
outlook busi pandem name april saw declin revenu due record-low
vacanc hospit outsid ward manag seem indic essenti
placement progress go live late lab custom complet inund ramp test
surpris given mayhem on-going hospit lab across countri end
anyon guess view howev acceler pheno system still thought solut major killer sepsi
think side pandem institut place greater valu diagnost algorithm
acceler help better tune could lot road travel wind destin
overal take-away acceler call rel simpl compani difficult posit given sole
focu lab test mean thing like reduc time system go-liv new placement even drive
increment util place system take bit paus notic progress made
think alreadi factor outlook stock overli concern paus progress
bit updat team serolog test partnership biocheck privat held vitro diagnost
compani subsidiari china-bas sophonix co ltd recal term agreement acceler
distribut ms-fast chemiluminesc immunoassay analyz well test detect igg
igm antibodi run machin two separ test box call team note
receiv sever indic interest work fda obtain eua also taken order emea
point discuss revenu potenti prematur continu think still bit odd marriag
bear watch even small amount revenu meaning repres offset cash burn especi
think increment cost essenti zero
first-quart result specif first quarter revenu came roughli line model million versu
million though placement sever miss target versu manag note quarter track ahead
plan februari march took custom attent quarter design back-
end weight term new placement halt new system sale led shortfal importantli howev util
revenu gener placement held plan total live system actual much better model
versu encourag indic procedur step recent revamp go-liv process
appear work
look forward believ revenu could come sever million dollar light previous expect new
placement essenti halt pandem could come even pressur util continu
hit caus vacanc hospit ward said would view one time natur
phenomenon side would suspect team everyth power drive go-liv
also drive util higher forefront think continu think pheno play
import role infecti diseas like sepsi
risk consid includ inabl expedit go-liv process custom funnel new account
yield suffici new placement nois potenti new entrant delay product pipelin opportun geograph
expans cash burn eat exist cash
bd bare magnitud scope crosswind hard model bd emerg fine
one compani list pre-releas result led us believ thing
come fairli close compani street expect fiscal second quarter prove correct
actual came slightli ahead estim revenu adjust earn per share despit bigger
headwind play specif revenu growth fxn compar guidanc approxim fxn
model adjust earn per share fxn versu guidanc
model surprisingli manag pull guidanc remain two quarter year revenu growth
call fxn
manag note pandem neg impact sale growth million
nearli doubl expect impact time fiscal first quarter call estim factor pandem
spread global fast major headwind came china impact
off-set tailwind europ saw increas demand critic healthcar devic initi use
bd test revers april busi trend someth low doubl digit
manag spent inordin amount time discuss headwind tailwind across three segment
subseg busi us interest thing focu gener recoveri aid
interact broader healthcar system tailwind potenti big revenu gain diagnost
particularli rapid antigen test instrument preview link posit side
hear manufactur ramp team target million test week end fiscal
year much bigger number thought
howev manag appear hedg bit commentari time uncertainti
accuraci assay current antibodi use know matter coupl week good
go begin access would run-rat billion-plu annual revenu opportun base modest price
assumpt though believ compani think aggress commit volum new
antibodi must chosen like delay team coupl month contrast commentari rapid
antigen assay less ambigu team seemingli convinc market immin
mayb bd bit cautiou ok certainli someth field follow-up call point
vaccin opportun area interest us within medic deliveri solut md segment gear
could nice opportun sell needl syring vaccin develop viru bd domin
market posit vial-bas vaccin would almost certainli deliv via bd infus product needl
syring run around would expect billion vaccin dose made anyon
actual success develop product govern agenc around world wait someth
discov begin think needl syring take long time scale addit billion-plu
certain govern place order meet demand entir popul govern
appear way behind endeavor bd wait go-ahead ramp manufactur variou govern
abl order actual place know world leader around globe read
note tell right go ahead prepar ahead time vaccin deliveri call bd get
alari pump updat lastli also focus alari pump situat increment cost effort requir
move beyond medic necess sale team limit quarter team saw million increment pump
sale medic necess though pandem tax healthcar system much fear right mani
area see reduct peak level would expect sort repeat next quarter beyond quarter
disclosur ad cost work done order abl file pump would
allow compani get back abl sell product freeli increment neg disclosur though
idea around natur delay hear fda inspect san diego result report
compani address word report constitut fda violat term specif
even sever
wrap togeth uncertainti underli busi determin precis land spot
compani growth rate next sever quarter nearli imposs exercis even well thought
ration framework could prove materi view framework deploy also like move around
significantli base news flow relat viru news around success failur vaccin treatment
test demand competit healthcar consum confid countri state local restrict suppli
chain updat like play import role outlook bd stori sentiment around
updat daili sometim hourli basi
think use low-double-digit declin compani saw april appropri start point low
water mark compani begin work part healthcar industri start reopen net
take-away us simpl cleanest call lot inform synthes outlook
uncertainti anyth realli chang competit busi ye slight delay work
get alari pump back market realli hospit system look swap put pump infrastructur
right doubt worri bd posit infus pump market leader jeopardi yet
beyond domin posit area relat pandem blood collect share ye
needl syring multipl higher share anyon els diversifi diagnost busi sever
shot goal solid underli busi capabl grow normal year think benefici
big boy industri strong liquid disciplin spend potenti meaning offset result
reiter outperform rate
risk consid issu bigger thought impact coronaviru expand price trend worsen
china macroeconom condit deterior new product launch meet expect regulatori challeng
expand new chief execut abil continu extract synergi large-scal activ
sever declin revenu april declin stabil begin bounc back bit
formal report first-quart result thursday even match pre-releas mid-april
prereleas continu pile clear compani immun call contain littl way surpris
regard trend seen date confirm thought busi perform april follow
call week team provid color quarter gave april result offer context thing
start get littl better think exactli case see sever declin
busi much april math due halt elect procedur statesid
countri around globe modest improv earli may
luckili fact remain go pent demand product sell patient need
cataract surgeri sooner rather later risk blind view seem like matter
core istent franchis begin march back level growth previous expect
procedur eventu come back realli anyon guess slope curv back normal look
like debat worthi ceo famili dinner opinion macro call patient
confid procedur think commentari around stabil pickup procedur
state alreadi open indic futur might look like
said light begin flicker ophthalmolog offic competit dynam still
manag pragmat note privat compani ivanti sight scienc still tri gain share
question view scale tip surgeon stick tri true istent devic
like use time motiv perform procedur bit potenti financi
incent sight scienc omni product benefici reimburs product specif
endors profession societi someth monitor suspect surgeon posit normal
consid financi gain procedur
addit note limit factor recoveri industri come capac system
handl bolu patient sure mani cataract procedur perform surgeon
baselin major determin suppli side equat addit even surgeon
theoret perform procedur idea sever patient wait room enter steril
oper room rel short period time seem far-fetch near-term think consid
recoveri manag call return normal monthli improv start fourth quarter
longer term think pandem anyth materi chang pipelin plan
compani time may chang slightli project discuss continu believ pipelin carri
valu well million impli base busi valuat billion busi expect
somewher order million revenu prior covid could like bounc back similar revenu
trajectori point restrict lift multipl around time seem inexpens even
competit concern much discuss reiter outperform rate
trend across three main busi segment april follow
 glaucoma daili sale compar plan exit march month april first
two week april sale non-exist small notch higher end month last
week small recoveri state reopen
intern glaucoma given countri differ shutdown procedur ration look
intern busi whole sale approxim versu plan april
corneal busi exit march approxim last throughout month april
relat pipelin team note feel confid product whose trial alreadi complet enrol
istent infinit epi-on therapi remain target target approv date late
respect assist part accommod fda guidanc express flexibl around patient
idos question whether pandem creat pushback trial yet fulli enrol
risk clinic site focus work backlog patient reopen compar
recruit new patient studi manag provid updat futur call think
conserv way look assum least small delay
manag discuss cut oper spend note remov approxim million quarterli cash
oper cash save second quarter versu plan look forward mean base oper expens figur
second quarter million team work
risk consid mig market growth share loss caus competit launch integr avedro could
caus short-term distract pipelin product excit yet receiv approv mani phase trial
could delay abil manag move puck forward endeavor someth
close watch
despit headwind volum remain strong bounc back cancer doesnt shelter place
guardant pre-announce result quiet last coupl month eager hear
busi updat compani case sinc ipo fall team disappoint
revenu million easili top million driven upsid averag sell price clinic test
came versu model upsid result full quarter payment non-lung
indic first time includ materi one-tim catch payment
clinic volum miss target biopharma volum model
think volum fell rate seen week prior middl march would probabl ad
anoth test addit million revenu speak well busi perform right like
mani manag team heard busi slow mid-march mention got bit wors april
get better last coupl week state begin slowli open low volum mark
surprisingli manag withdrew guidanc due uncertainti pace recoveri volum run
overal anoth big win quarter guardant despit headwind emerg mid-march
busi still put strong result addit situat could help drive even clinician favor non-
invas blood collect hospital-bas biopsi procedur requir collect tissu biopsi recoveri test
start playout fear covid lose certainti die without cancer treatment compani
domin posit liquid biopsi test healthi balanc sheet grow set biopharma relationship
current revenu long-term revenu potenti continu recommend stock anticip updat
model come day
offer may new tailwind cours compani main product liquid biopsi offer late stage
cancer therapi select slowdown volum mention patient unfortun
manifest point late stage patient diagnos biopsi done think notion
option done via blood draw instead tissu biopsi procedur big deal new world immun
compromis patient like like want avoid hospit procedur much possibl
non-invasive collect benefit combin expand reimburs coverag next year
plethora data pile indic liquid biopsi effect use primari sampl type get
comprehens genom profil influenc therapi select recogn chang medicin come
easili light switch drive volum think catalyst chang across healthcar
system see liquid biopsi could one biggest beneficiari diagnost long-term seem
inevit liquid biopsi prefer sampl test may move along
pipelin pipelin updat mainli around colorect cancer-screen assay first enrol slow
addit enrol site could help team catch meet enrol goal either way
think coupl month delay much big deal second compani highlight data releas
virtual ddw meet last weekend studi team use cancer cohort prior valid data use
case chang control group healthi popul screen neg advanc adenoma
cancer colonoscopi re-run sampl shown specif initi result jump
specif sensit also got bit boost
manag believ better real world represent test discuss manag post-cal
discuss understand went thing way still linger question need
review either way still coupl year away see data full dataset prospect trial
believ debat mere specul take approach compani abl
demonstr high earli cancer sensit use blood sampl type see evid proper popul
possibl hesit give much valuat support project
assay develop manag surpris everyon announc develop saliva-bas
assay use california help test employe front-lin worker similar effort
wisconsin though guardant use next gener sequenc readout analyst mystifi move
featur heavili session support notion develop assay order help fill test
gap commun way believ busi model chang someth go give whole lot
valuat credit team abl test day may scale would lead million
revenu per day insignific readi make guardant test play
risk consid competit crowd liquid biopsi market difficulti penetr
clinic market lack visibl biopharmaceut partnership lack success trial commerci
pipelin product screen assay
price common stock public compani mention report follow
